stroke
Conditions
Interventions
Oral Antiplatelet Agents:atiplatelet Agents was administrated orally
tirofiban:tirofiban was administrated intravenously
Sponsors
Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with acute ischemic stroke and eligible for treatment within 48 hours after onset; 2) Patients capable of completing cranial MRI and meeting one of the following criteria: a) perforating artery infarct in basal ganglia with axial MRI scanning of =3 layers (layer thickness of 0.5mm); b) perforating artery infarct attributed to the occlusion at the vascular opening; c) perforating artery infarct in the ventral pons; d) perforating artery infarct with TIA neurological deterioration within 48 hours after onset; 3) With or without stenosis in carrier arteries; 4) Aged between 18 and 80 years, irrespective of gender; 5) Informed consent obtained from either the subject or their legal representative.
Exclusion criteria
Exclusion criteria: 1) receive intravenous or endovascular treatment (thrombectomy or thrombolysis) for the current ischemic stroke; 2) stenosis in cephalocervical artery for more than 50%; 3) other definite or suspected causes of ischemic stroke, including arteritis, vasospasm, moyamoya disease, etc. 4) with atrial fibrillation, valvular heart disease, acute myocardial infarction within 30 days before enrollment; 5) bleeding tendency (platelet count 180mmHg or diastolic blood pressure >110mmHg); 11) pregnant or perinatal women; 12) patients with severe systemic diseases including diseases requiring for vital organ transplantation, malignant diseases or impaired respiratory function with life expectancy of 400mg/dl or ketone > 2+) and those requiring general anesthesia for elective surgery recently; 13) inability to understand and/or comply with study procedures and/or follow-up due to mental disorders, cognitive or emotional disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of early neurolgical progression; | — |
Secondary
| Measure | Time frame |
|---|---|
| infarct volume 7 days post administration;Incidence of cardiovascular and cerebrovascular events;The change of NIHSS;The change of mRS;The change ; | — |
Countries
China
Contacts
Public ContactTian Chenglin
Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
Outcome results
None listed